OTCMKTS:CCEL

Cryo-Cell International Competitors

$9.92
0.00 (0.00 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.90
Now: $9.92
$9.95
50-Day Range
$9.00
MA: $9.37
$10.00
52-Week Range
$4.52
Now: $9.92
$11.50
Volume41,939 shs
Average Volume9,577 shs
Market Capitalization$75.10 million
P/E Ratio24.80
Dividend YieldN/A
Beta0.29

Competitors

Cryo-Cell International (OTCMKTS:CCEL) Vs. CLBS, BXRX, GRNV, EMMA, PFHOD, and CTYX

Should you be buying CCEL stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to Cryo-Cell International, including Caladrius Biosciences (CLBS), Baudax Bio (BXRX), GreenVision Acquisition (GRNV), Emmaus Life Sciences (EMMA), Pacific Health Care Organization (PFHOD), and Curative Biotechnology (CTYX).

Caladrius Biosciences (NASDAQ:CLBS) and Cryo-Cell International (OTCMKTS:CCEL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Caladrius Biosciences has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Cryo-Cell International has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.

Insider & Institutional Ownership

9.0% of Caladrius Biosciences shares are held by institutional investors. Comparatively, 1.0% of Cryo-Cell International shares are held by institutional investors. 10.3% of Caladrius Biosciences shares are held by insiders. Comparatively, 53.8% of Cryo-Cell International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Caladrius Biosciences and Cryo-Cell International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.86
Cryo-Cell International$31.80 million2.36$2.29 millionN/AN/A

Cryo-Cell International has higher revenue and earnings than Caladrius Biosciences.

Profitability

This table compares Caladrius Biosciences and Cryo-Cell International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Caladrius BiosciencesN/A-68.33%-57.61%
Cryo-Cell International10.39%-58.74%7.30%

Analyst Ratings

This is a breakdown of current ratings and target prices for Caladrius Biosciences and Cryo-Cell International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Caladrius Biosciences01302.75
Cryo-Cell International0000N/A

Caladrius Biosciences currently has a consensus price target of $10.00, suggesting a potential upside of 517.28%. Given Caladrius Biosciences' higher probable upside, research analysts plainly believe Caladrius Biosciences is more favorable than Cryo-Cell International.

Summary

Cryo-Cell International beats Caladrius Biosciences on 7 of the 11 factors compared between the two stocks.

Baudax Bio (NASDAQ:BXRX) and Cryo-Cell International (OTCMKTS:CCEL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Baudax Bio has a beta of 2.56, suggesting that its stock price is 156% more volatile than the S&P 500. Comparatively, Cryo-Cell International has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Baudax Bio and Cryo-Cell International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Baudax Bio00203.00
Cryo-Cell International0000N/A

Baudax Bio currently has a consensus price target of $13.50, suggesting a potential upside of 1,150.00%. Given Baudax Bio's higher probable upside, research analysts plainly believe Baudax Bio is more favorable than Cryo-Cell International.

Earnings and Valuation

This table compares Baudax Bio and Cryo-Cell International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31
Cryo-Cell International$31.80 million2.36$2.29 millionN/AN/A

Cryo-Cell International has higher revenue and earnings than Baudax Bio.

Insider & Institutional Ownership

7.9% of Baudax Bio shares are held by institutional investors. Comparatively, 1.0% of Cryo-Cell International shares are held by institutional investors. 13.1% of Baudax Bio shares are held by insiders. Comparatively, 53.8% of Cryo-Cell International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Baudax Bio and Cryo-Cell International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Baudax BioN/AN/AN/A
Cryo-Cell International10.39%-58.74%7.30%

Summary

Cryo-Cell International beats Baudax Bio on 6 of the 11 factors compared between the two stocks.

Cryo-Cell International (OTCMKTS:CCEL) and GreenVision Acquisition (NASDAQ:GRNV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cryo-Cell International and GreenVision Acquisition, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryo-Cell International0000N/A
GreenVision Acquisition0000N/A

Valuation and Earnings

This table compares Cryo-Cell International and GreenVision Acquisition's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryo-Cell International$31.80 million2.36$2.29 millionN/AN/A
GreenVision AcquisitionN/AN/AN/AN/AN/A

Cryo-Cell International has higher revenue and earnings than GreenVision Acquisition.

Insider and Institutional Ownership

1.0% of Cryo-Cell International shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. 53.8% of Cryo-Cell International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cryo-Cell International and GreenVision Acquisition's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryo-Cell International10.39%-58.74%7.30%
GreenVision AcquisitionN/AN/AN/A

Summary

Cryo-Cell International beats GreenVision Acquisition on 4 of the 6 factors compared between the two stocks.

Cryo-Cell International (OTCMKTS:CCEL) and Emmaus Life Sciences (OTCMKTS:EMMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Cryo-Cell International has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Emmaus Life Sciences has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cryo-Cell International and Emmaus Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryo-Cell International0000N/A
Emmaus Life Sciences0000N/A

Valuation and Earnings

This table compares Cryo-Cell International and Emmaus Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryo-Cell International$31.80 million2.36$2.29 millionN/AN/A
Emmaus Life Sciences$1.32 million48.62$-2,370,000.00N/AN/A

Cryo-Cell International has higher revenue and earnings than Emmaus Life Sciences.

Insider and Institutional Ownership

1.0% of Cryo-Cell International shares are owned by institutional investors. Comparatively, 0.1% of Emmaus Life Sciences shares are owned by institutional investors. 53.8% of Cryo-Cell International shares are owned by insiders. Comparatively, 36.9% of Emmaus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cryo-Cell International and Emmaus Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryo-Cell International10.39%-58.74%7.30%
Emmaus Life SciencesN/AN/AN/A

Summary

Cryo-Cell International beats Emmaus Life Sciences on 6 of the 9 factors compared between the two stocks.

Cryo-Cell International (OTCMKTS:CCEL) and Pacific Health Care Organization (OTCMKTS:PFHOD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Cryo-Cell International has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Pacific Health Care Organization has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cryo-Cell International and Pacific Health Care Organization, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryo-Cell International0000N/A
Pacific Health Care Organization0000N/A

Valuation and Earnings

This table compares Cryo-Cell International and Pacific Health Care Organization's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryo-Cell International$31.80 million2.36$2.29 millionN/AN/A
Pacific Health Care Organization$6.80 million2.35$1.36 millionN/AN/A

Cryo-Cell International has higher revenue and earnings than Pacific Health Care Organization.

Insider and Institutional Ownership

1.0% of Cryo-Cell International shares are owned by institutional investors. 53.8% of Cryo-Cell International shares are owned by insiders. Comparatively, 61.6% of Pacific Health Care Organization shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cryo-Cell International and Pacific Health Care Organization's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryo-Cell International10.39%-58.74%7.30%
Pacific Health Care Organization16.87%14.47%12.96%

Summary

Pacific Health Care Organization beats Cryo-Cell International on 5 of the 9 factors compared between the two stocks.

Cryo-Cell International (OTCMKTS:CCEL) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Institutional and Insider Ownership

1.0% of Cryo-Cell International shares are owned by institutional investors. 53.8% of Cryo-Cell International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Cryo-Cell International has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, meaning that its stock price is 3,294% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cryo-Cell International and Curative Biotechnology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryo-Cell International$31.80 million2.36$2.29 millionN/AN/A
Curative BiotechnologyN/AN/AN/AN/AN/A

Cryo-Cell International has higher revenue and earnings than Curative Biotechnology.

Profitability

This table compares Cryo-Cell International and Curative Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryo-Cell International10.39%-58.74%7.30%
Curative BiotechnologyN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cryo-Cell International and Curative Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryo-Cell International0000N/A
Curative Biotechnology0000N/A

Summary

Cryo-Cell International beats Curative Biotechnology on 6 of the 7 factors compared between the two stocks.


Cryo-Cell International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.62flat$96.39 millionN/A-2.53Decrease in Short Interest
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.08flat$75.75 millionN/A-0.31Analyst Downgrade
GRNV
GreenVision Acquisition
0.3$10.19flat$72.96 millionN/A0.00
Emmaus Life Sciences logo
EMMA
Emmaus Life Sciences
0.2$1.31flat$62.70 million$1.32 million0.00
PFHOD
Pacific Health Care Organization
0.5$1.25flat$52.48 million$6.80 million0.00Gap Up
CTYX
Curative Biotechnology
0.0$0.15flat$40.17 millionN/A0.00
BRTXQ
BioRestorative Therapies
0.0$0.01flat$16.40 million$110,000.00-0.01
BioRestorative Therapies logo
BRTX
BioRestorative Therapies
0.6$0.01flat$16.39 million$110,000.000.00
PFHO
Pacific Health Care Organization
0.8$1.12flat$14.34 million$7.33 million0.00Gap Up
GNOW
American Caresource
0.7$0.01flat$124,000.00N/A0.00
HYBE
Hybrid Energy
0.0$0.00flat$0.00N/A0.00Gap Down
QMED
QMed
0.2$0.00flat$0.00N/A0.00
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.